Cibus, Inc.
CBUS
NASDAQ·Healthcare·Biotechnology·Mkt cap $119.1M
$1.56
▲ 0.00%
P/E
-1.08
Mkt Cap
$119.1M
52-Wk Range
$1.09–$4.19
52-Week Range
$1.09 - $4.19
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 17.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary plant breeding and trait technology
- Recurring royalty revenue model with high margins
- Strategic partnerships with major seed companies
- Sustainable agriculture focus aligned with global ESG trends
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Moderate growth ahead
Rising global demand for sustainable farming solutions
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+12.2% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CBUS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.29 vs -$0.19 consensus (-52.6% surprise). Revenue of $994.0K vs $1.7M expected (-41.7%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-52.6%
Revenue trend · last 8Q
—
—
+90%
+11%
-63%
-13%
+63%
+7%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.7M
$1.2M
$1.0M
$933.0K
$615.0K
$1.1M
$1.7M
$994.0K
Margins · last 8Q
Gross
-48.7%
Profit
-2227.9%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Jefferies · Mar 25, 2026
vs Industry
How CBUS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related